Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CETP | P11597 | 3/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7341230 | 0.91 | TSHR (0.55) | TSHRHPGDCETPALDH1A1FOLH1 | |
| SCHEMBL7336647 | 0.84 | TSHR (0.51) | TSHRHPGDCETPALDH1A1FOLH1 | |
| SCHEMBL5028595 | 0.84 | TSHR (0.60) | TSHRHPGDCETPSRCPDPK1 | |
| SCHEMBL3367144 | 0.83 | TSHR (0.64) | TSHRHPGDCETPSRCPDPK1 | |
| SCHEMBL5327008 | 0.83 | TSHR (0.63) | TSHRCETPSRCPDPK1MTOR | |
| SCHEMBL4154492 | 0.81 | TSHR (0.56) | TSHRHPGDCETPSRCPDPK1 | |
| SCHEMBL2469341 | 0.81 | TSHR (0.56) | TSHRHPGDCETPSRCPDPK1 | |
| SCHEMBL7520596 | 0.81 | TSHR (0.67) | TSHRHPGDCETPSRCPDPK1 | |
| SCHEMBL5850148 | 0.81 | TSHR (0.61) | TSHRHPGDCETPSRCPDPK1 | |
| SCHEMBL413304 | 0.80 | TSHR (0.60) | TSHRCETPSRCALDH1A1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116913-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TEXAS A & M UNIV SYS (US) | 2026-04-30 | — | — | US | disclosed |
| US-12509487-B2 | Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250170156-A1 | TOLL-LIKE RECEPTOR LIGANDS | INIMMUNE CORP (US) | 2025-05-29 | — | — | US | disclosed |
| US-12150948-B2 | Toll-like receptor ligands | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4410802-A2 | TOLL-LIKE RECEPTOR LIGANDS | INIMMUNE CORPORATION (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-111867623-B | TOLL-like receptor ligands | 英尼穆内公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-3752182-B1 | TOLL-LIKE RECEPTOR LIGANDS | INIMMUNE CORP (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20230151052-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-05-18 | — | — | US | disclosed |
| US-20230151052-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-05-18 | — | — | US | disclosed |
| US-20230055805-A1 | TOLL-LIKE RECEPTOR LIGANDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-02-23 | — | — | US | disclosed |
| WO-2007050732-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR | ABBOTT LABORATORIES (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001055082-A2 | INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-0691985-B1 | PHOSPHONOMETHYLDIPEPTIDES | MERRELL PHARMA INC (US) | 2000-05-03 | — | — | EP | disclosed |
| US-5952327-A | NEUTRAL ENDOPEPTIDASE INHIBITORS; TREATMENT OF CARDIOVASCULAR DISORDERS | SOLVAY PHARMACEUTICALS GMBH (DE) | 1999-09-14 | — | — | US | disclosed |
| US-5608078-A | Phosphonomethyldipeptides and process for preparation thereof | MERRELL PHARMACEUTICALS INC. (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0691985-A1 | PHOSPHONOMETHYLDIPEPTIDES | MERRELL PHARMACEUTICALS INC. (US) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994022908-A1 | PHOSPHONOMETHYLDIPEPTIDES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0618224-A1 | Phosphonomethyldipeptides | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151052-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | CYP11B2, CYP21A2, CYP11B1 | TSHR 1213/4885HPGD 60/4885CETP 972/4885 |
| US-20230055805-A1 | TOLL-LIKE RECEPTOR LIGANDS | TLR1, TLR4, TLR6 | TSHR 1009/4885HPGD 3219/4885CETP 846/4885 |
| US-12509487-B2 | Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders | SLC6A11, GABRE, SLC6A13 | TSHR 2032/4885HPGD 344/4885CETP 2436/4885 |
| US-12150948-B2 | Toll-like receptor ligands | TLR1, TLR4, TLR6 | TSHR 1009/4885HPGD 3219/4885CETP 846/4885 |
| US-20260116913-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | CHRNA9, HSD3B2, HSD3B1 | TSHR 223/4885HPGD 482/4885CETP 1915/4885 |
| US-20250170156-A1 | TOLL-LIKE RECEPTOR LIGANDS | TLR1, TLR4, TLR6 | TSHR 1009/4885HPGD 3219/4885CETP 846/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | TSHR 4782/4885HPGD 1843/4885CETP 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.